Please use this identifier to cite or link to this item:
https://hdl.handle.net/11147/9455
Title: | AKT inhibitor ARQ 092 and sorafenib additively inhibit progression of hepatocellular carcinoma and improve immune system in cirrhotic rat model | Authors: | Jilkova, Z. M. Zeybek Kuyucu, Ayça Kurma, K. Pour, S. T. A. Roth, G. S. Abbadessa, G. Decaens, T. |
Publisher: | Elsevier | Abstract: | Background and Aims: Hepatocellular carcinoma (HCC) is often diagnosed at advanced stages with limited number of therapeutic options. Longer exposure to classical treatment of advanced HCC, sorafenib, often over-activates AKT pathway, leading to HCC resistance. Moreover, AKT pathway itself is activated in almost half of HCC cases. Therefore, we investigated the efficacy of combination of Sorafenib with allosteric Akt inhibitor ARQ 092 in a DEN-induced cirrhotic rat model with HCC. | Description: | International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver -- APR 19-23, 2017 -- Amsterdam, NETHERLANDS | URI: | https://doi.org/10.1016/S0168-8278(17)31736-1 https://hdl.handle.net/11147/9455 |
ISSN: | 0168-8278 1600-0641 |
Appears in Collections: | Bioengineering / Biyomühendislik WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Files in This Item:
File | Size | Format | |
---|---|---|---|
1-s2.0-S0168827817317361-main.pdf | 61.74 kB | Adobe PDF | View/Open |
CORE Recommender
Page view(s)
162
checked on Aug 12, 2024
Download(s)
86
checked on Aug 12, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.